AChE inhibition with 10–14hr half-life causes ACh accumulation. Even 50mcg produces clinically meaningful AChE blockade comparable to prescription inhibitors.

At 200–600mg standardized extract, HPA axis modulation is clinically relevant. Bell-curve dose-response means higher doses can be less effective. Below ~100mg, effect is subclinical.

Chronic daily intake ≥100mg upregulates adenosine A1/A2A receptor density within 7–14 days.

At ≥600mg, NAC shifts glutathione synthesis and glutamatergic signaling via system Xc-. Cycling is more theoretical (redox hormesis) than proven receptor adaptation.

AMPK mechanism does not classically downregulate. Cycling is precautionary (hepatoprotective, GI tolerance), not pharmacodynamic. Studies show sustained effects for 3–12 months.

At ≥300mg, significantly raises brain choline and ACh levels. Muscarinic receptor desensitization possible with chronic high dosing. Below 150mg acts as nutritional choline support.

At ≥250mg, significant CYP1A2 enzyme induction and SIRT1 activation. Chronic use may induce its own metabolism (autoinduction). Below 100mg acts as antioxidant support.

At ≥10mg, measurably alters mitochondrial redox state. Biphasic (hormetic) dose-response: low doses enhance, high doses inhibit. Exceeding ~2mg/kg becomes counterproductive.

At ≥3mg (supraphysiological), negative feedback on pineal production and potential MT1/MT2 desensitization. Physiological doses (0.3–1mg) show minimal receptor downregulation.

At ≥100mg, significantly elevates synaptic 5-HT. Chronic high-dose use (≥200mg) causes 5-HT2A receptor downregulation within 2–4 weeks, paralleling SSRI tachyphylaxis.

Oral GABA has limited BBB permeability; effects are primarily peripheral. Tolerance evidence is minimal.

At 300–600mg KSM-66, reduces cortisol 20–30% via HPA axis suppression. Also modulates thyroid (↑T3/T4 by 19–41%) and GABAergic tone. Case report of adrenal insufficiency at 950mg/day.

At ≥500mg extract, significant immune upregulation via beta-glucan macrophage/NK cell activation. Chronic immune stimulation could shift Th1/Th2 balance. Cycling allows recalibration.

At ≥500mg standardized extract, measurable effects on ATP production via cordycepin (adenosine analog). Chronic adenosine receptor sensitivity downregulation possible.

At ≥150mg of 20% extract (~30mg bacosides), AChE inhibition + serotonin/GABA modulation + cerebral blood flow effects emerge after 8–12 weeks. Below 75mg is sub-clinical for cycling.

At ≥200mg standardized extract, measurable hormonal effects (LH/FSH → testosterone). HPG axis adapts to supported testosterone environment. Traditional Malay usage was cyclical.

At ≥500mg leaf powder, measurable Nrf2 activation via isothiocyanates. Chronic Nrf2 activation may paradoxically suppress the pathway via Keap1 adaptation (hormesis). Theoretical.